[1] [1] Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023, 118(17):3272-3287.

[2] [2] Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review[J]. Heart, 2022, 108(17):1351-1360.

[3] [3] Reddy YNV, Borlaug BA, Gersh BJ. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction[J]. Circulation, 2022, 146(4):339-357.

[4] [4] Nishikimi T, Nakagawa Y. B-type natriuretic peptide (BNP) revisited-is BNP still a biomarker for heart failure in the angiotensin receptor/neprilysin inhibitor era[J]? Biology (Basel), 2022, 11(7):1034.

[5] [5] Docherty KF, Vaduganathan M, Solomon SD, et al. Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF[J]. JACC Heart Fail, 2020, 8(10):800-810.

[6] [6] Honka H, Solis-Herrera C, Triplitt C, et al. Therapeutic manipulation of myocardial metabolism: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2021, 77(16):2022-2039.

[7] [7] Xinshuang Z, Lei S, Hailong Y, et al. Compound Gaoziban tablet alleviates depression toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B pathway[J]. J Tradit Chin Med, 2022, 42(6):956-964.

[10] [10] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.

[11] [11] Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week[J]. J Am Coll Cardiol, 2023, 81(4):413-424.

[12] [12] Parkash R, Wells GA, Rouleau J, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial[J]. Circulation, 2022, 145(23):1693-1704.

[13] [13] Shalaby AA. Atrial fibrillation and congestive heart failure: a wicked alliance about to unravel[J]. JACC Clin Electrophysiol, 2022, 8(11):1367-1368.

[14] [14] Infeld M, Wahlberg K, Cicero J, et al. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial[J]. JAMA Cardiol, 2023, 8(3):213-221.

[15] [15] Vader JM, Givertz MM, Starling RC, et al. Tolerability of sacubitril/valsartan in patients with advanced heart failure: analysis of the LIFE trial run-in[J]. JACC Heart Fail, 2022, 10(7):449-456.

[16] [16] Bozkurt B, Nair AP, Misra A, et al. Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions[J]. JACC Basic Transl Sci, 2022, 8(1):88-105.

[17] [17] Wagner D, Kronick SL, Nawer H, et al. Comparative effectiveness of amiodarone and lidocaine for the treatment of in-hospital cardiac arrest[J]. Chest, 2023, 163(5):1109-1119.

[18] [18] Codina P, Domingo M, Barcel E, et al. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension[J]. ESC Heart Fail, 2022, 9(4):2170-2180.

[19] [19] Savarese G, Kishi T, Vardeny O, et al. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)[J]. JACC Heart Fail, 2023, 11(1):1-14.

[20] [20] Mehran R, Steg PG, Pfeffer MA, et al. The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial[J]. Circulation, 2022, 146(23):1749-1757.

[21] [21] Dridi H, Kushnir A, Zalk R, et al. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target[J]. Nat Rev Cardiol, 2020, 17(11):732-747.

[22] [22] Lopaschuk GD, Karwi QG, Tian R, et al. Cardiac energy metabolism in heart failure[J]. Circ Res, 2021, 128(10):1487-1513.